Global Pneumococcal Vaccine Polyvalent Market Growth 2025-2031

October 2025 | 84 pages | ID: G42498ECF2FEN
LP Information

Abstracts

The global Pneumococcal Vaccine Polyvalent market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Pneumococcal vaccines are vaccines against the bacteria Streptococcus pneumoniae. Their use can prevent some cases of pneumonia, meningitis, and sepsis.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the ?Pneumococcal Vaccine Polyvalent Industry Forecast? looks at past sales and reviews total world Pneumococcal Vaccine Polyvalent sales in 2024, providing a comprehensive analysis by region and market sector of projected Pneumococcal Vaccine Polyvalent sales for 2025 through 2031. With Pneumococcal Vaccine Polyvalent sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pneumococcal Vaccine Polyvalent industry.

This Insight Report provides a comprehensive analysis of the global Pneumococcal Vaccine Polyvalent landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pneumococcal Vaccine Polyvalent portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Pneumococcal Vaccine Polyvalent market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pneumococcal Vaccine Polyvalent and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pneumococcal Vaccine Polyvalent.

This report presents a comprehensive overview, market shares, and growth opportunities of Pneumococcal Vaccine Polyvalent market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Prevnar 13
• Pneumovax23

Segmentation by Application:

• 18 Years and Younger
• 19 To 64 Years Old
• 65 Years and Older

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Merck & Co.
• Pfizer

Key Questions Addressed in this Report

What is the 10-year outlook for the global Pneumococcal Vaccine Polyvalent market?
What factors are driving Pneumococcal Vaccine Polyvalent market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pneumococcal Vaccine Polyvalent market opportunities vary by end market size?
How does Pneumococcal Vaccine Polyvalent break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Pneumococcal Vaccine Polyvalent Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Pneumococcal Vaccine Polyvalent by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Pneumococcal Vaccine Polyvalent by Country/Region, 2020, 2024 & 2031
2.2 Pneumococcal Vaccine Polyvalent Segment by Type
  2.2.1 Prevnar 13
  2.2.2 Pneumovax23
2.3 Pneumococcal Vaccine Polyvalent Sales by Type
  2.3.1 Global Pneumococcal Vaccine Polyvalent Sales Market Share by Type (2020-2025)
  2.3.2 Global Pneumococcal Vaccine Polyvalent Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Pneumococcal Vaccine Polyvalent Sale Price by Type (2020-2025)
2.4 Pneumococcal Vaccine Polyvalent Segment by Application
  2.4.1 18 Years and Younger
  2.4.2 19 To 64 Years Old
  2.4.3 65 Years and Older
2.5 Pneumococcal Vaccine Polyvalent Sales by Application
  2.5.1 Global Pneumococcal Vaccine Polyvalent Sale Market Share by Application (2020-2025)
  2.5.2 Global Pneumococcal Vaccine Polyvalent Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Pneumococcal Vaccine Polyvalent Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Pneumococcal Vaccine Polyvalent Breakdown Data by Company
  3.1.1 Global Pneumococcal Vaccine Polyvalent Annual Sales by Company (2020-2025)
  3.1.2 Global Pneumococcal Vaccine Polyvalent Sales Market Share by Company (2020-2025)
3.2 Global Pneumococcal Vaccine Polyvalent Annual Revenue by Company (2020-2025)
  3.2.1 Global Pneumococcal Vaccine Polyvalent Revenue by Company (2020-2025)
  3.2.2 Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Company (2020-2025)
3.3 Global Pneumococcal Vaccine Polyvalent Sale Price by Company
3.4 Key Manufacturers Pneumococcal Vaccine Polyvalent Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Pneumococcal Vaccine Polyvalent Product Location Distribution
  3.4.2 Players Pneumococcal Vaccine Polyvalent Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR PNEUMOCOCCAL VACCINE POLYVALENT BY GEOGRAPHIC REGION

4.1 World Historic Pneumococcal Vaccine Polyvalent Market Size by Geographic Region (2020-2025)
  4.1.1 Global Pneumococcal Vaccine Polyvalent Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Pneumococcal Vaccine Polyvalent Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Pneumococcal Vaccine Polyvalent Market Size by Country/Region (2020-2025)
  4.2.1 Global Pneumococcal Vaccine Polyvalent Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Pneumococcal Vaccine Polyvalent Annual Revenue by Country/Region (2020-2025)
4.3 Americas Pneumococcal Vaccine Polyvalent Sales Growth
4.4 APAC Pneumococcal Vaccine Polyvalent Sales Growth
4.5 Europe Pneumococcal Vaccine Polyvalent Sales Growth
4.6 Middle East & Africa Pneumococcal Vaccine Polyvalent Sales Growth

5 AMERICAS

5.1 Americas Pneumococcal Vaccine Polyvalent Sales by Country
  5.1.1 Americas Pneumococcal Vaccine Polyvalent Sales by Country (2020-2025)
  5.1.2 Americas Pneumococcal Vaccine Polyvalent Revenue by Country (2020-2025)
5.2 Americas Pneumococcal Vaccine Polyvalent Sales by Type (2020-2025)
5.3 Americas Pneumococcal Vaccine Polyvalent Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Pneumococcal Vaccine Polyvalent Sales by Region
  6.1.1 APAC Pneumococcal Vaccine Polyvalent Sales by Region (2020-2025)
  6.1.2 APAC Pneumococcal Vaccine Polyvalent Revenue by Region (2020-2025)
6.2 APAC Pneumococcal Vaccine Polyvalent Sales by Type (2020-2025)
6.3 APAC Pneumococcal Vaccine Polyvalent Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Pneumococcal Vaccine Polyvalent by Country
  7.1.1 Europe Pneumococcal Vaccine Polyvalent Sales by Country (2020-2025)
  7.1.2 Europe Pneumococcal Vaccine Polyvalent Revenue by Country (2020-2025)
7.2 Europe Pneumococcal Vaccine Polyvalent Sales by Type (2020-2025)
7.3 Europe Pneumococcal Vaccine Polyvalent Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Pneumococcal Vaccine Polyvalent by Country
  8.1.1 Middle East & Africa Pneumococcal Vaccine Polyvalent Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Pneumococcal Vaccine Polyvalent Revenue by Country (2020-2025)
8.2 Middle East & Africa Pneumococcal Vaccine Polyvalent Sales by Type (2020-2025)
8.3 Middle East & Africa Pneumococcal Vaccine Polyvalent Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pneumococcal Vaccine Polyvalent
10.3 Manufacturing Process Analysis of Pneumococcal Vaccine Polyvalent
10.4 Industry Chain Structure of Pneumococcal Vaccine Polyvalent

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Pneumococcal Vaccine Polyvalent Distributors
11.3 Pneumococcal Vaccine Polyvalent Customer

12 WORLD FORECAST REVIEW FOR PNEUMOCOCCAL VACCINE POLYVALENT BY GEOGRAPHIC REGION

12.1 Global Pneumococcal Vaccine Polyvalent Market Size Forecast by Region
  12.1.1 Global Pneumococcal Vaccine Polyvalent Forecast by Region (2026-2031)
  12.1.2 Global Pneumococcal Vaccine Polyvalent Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Pneumococcal Vaccine Polyvalent Forecast by Type (2026-2031)
12.7 Global Pneumococcal Vaccine Polyvalent Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Merck & Co.
  13.1.1 Merck & Co. Company Information
  13.1.2 Merck & Co. Pneumococcal Vaccine Polyvalent Product Portfolios and Specifications
  13.1.3 Merck & Co. Pneumococcal Vaccine Polyvalent Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Merck & Co. Main Business Overview
  13.1.5 Merck & Co. Latest Developments
13.2 Pfizer
  13.2.1 Pfizer Company Information
  13.2.2 Pfizer Pneumococcal Vaccine Polyvalent Product Portfolios and Specifications
  13.2.3 Pfizer Pneumococcal Vaccine Polyvalent Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Pfizer Main Business Overview
  13.2.5 Pfizer Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Pneumococcal Vaccine Polyvalent Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Pneumococcal Vaccine Polyvalent Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Prevnar 13
Table 4. Major Players of Pneumovax23
Table 5. Global Pneumococcal Vaccine Polyvalent Sales by Type (2020-2025) & (K Units)
Table 6. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Type (2020-2025)
Table 7. Global Pneumococcal Vaccine Polyvalent Revenue by Type (2020-2025) & ($ million)
Table 8. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2020-2025)
Table 9. Global Pneumococcal Vaccine Polyvalent Sale Price by Type (2020-2025) & (USD/Unit)
Table 10. Global Pneumococcal Vaccine Polyvalent Sale by Application (2020-2025) & (K Units)
Table 11. Global Pneumococcal Vaccine Polyvalent Sale Market Share by Application (2020-2025)
Table 12. Global Pneumococcal Vaccine Polyvalent Revenue by Application (2020-2025) & ($ million)
Table 13. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2020-2025)
Table 14. Global Pneumococcal Vaccine Polyvalent Sale Price by Application (2020-2025) & (USD/Unit)
Table 15. Global Pneumococcal Vaccine Polyvalent Sales by Company (2020-2025) & (K Units)
Table 16. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Company (2020-2025)
Table 17. Global Pneumococcal Vaccine Polyvalent Revenue by Company (2020-2025) & ($ millions)
Table 18. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Company (2020-2025)
Table 19. Global Pneumococcal Vaccine Polyvalent Sale Price by Company (2020-2025) & (USD/Unit)
Table 20. Key Manufacturers Pneumococcal Vaccine Polyvalent Producing Area Distribution and Sales Area
Table 21. Players Pneumococcal Vaccine Polyvalent Products Offered
Table 22. Pneumococcal Vaccine Polyvalent Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Pneumococcal Vaccine Polyvalent Sales by Geographic Region (2020-2025) & (K Units)
Table 26. Global Pneumococcal Vaccine Polyvalent Sales Market Share Geographic Region (2020-2025)
Table 27. Global Pneumococcal Vaccine Polyvalent Revenue by Geographic Region (2020-2025) & ($ millions)
Table 28. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Geographic Region (2020-2025)
Table 29. Global Pneumococcal Vaccine Polyvalent Sales by Country/Region (2020-2025) & (K Units)
Table 30. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Country/Region (2020-2025)
Table 31. Global Pneumococcal Vaccine Polyvalent Revenue by Country/Region (2020-2025) & ($ millions)
Table 32. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Country/Region (2020-2025)
Table 33. Americas Pneumococcal Vaccine Polyvalent Sales by Country (2020-2025) & (K Units)
Table 34. Americas Pneumococcal Vaccine Polyvalent Sales Market Share by Country (2020-2025)
Table 35. Americas Pneumococcal Vaccine Polyvalent Revenue by Country (2020-2025) & ($ millions)
Table 36. Americas Pneumococcal Vaccine Polyvalent Sales by Type (2020-2025) & (K Units)
Table 37. Americas Pneumococcal Vaccine Polyvalent Sales by Application (2020-2025) & (K Units)
Table 38. APAC Pneumococcal Vaccine Polyvalent Sales by Region (2020-2025) & (K Units)
Table 39. APAC Pneumococcal Vaccine Polyvalent Sales Market Share by Region (2020-2025)
Table 40. APAC Pneumococcal Vaccine Polyvalent Revenue by Region (2020-2025) & ($ millions)
Table 41. APAC Pneumococcal Vaccine Polyvalent Sales by Type (2020-2025) & (K Units)
Table 42. APAC Pneumococcal Vaccine Polyvalent Sales by Application (2020-2025) & (K Units)
Table 43. Europe Pneumococcal Vaccine Polyvalent Sales by Country (2020-2025) & (K Units)
Table 44. Europe Pneumococcal Vaccine Polyvalent Revenue by Country (2020-2025) & ($ millions)
Table 45. Europe Pneumococcal Vaccine Polyvalent Sales by Type (2020-2025) & (K Units)
Table 46. Europe Pneumococcal Vaccine Polyvalent Sales by Application (2020-2025) & (K Units)
Table 47. Middle East & Africa Pneumococcal Vaccine Polyvalent Sales by Country (2020-2025) & (K Units)
Table 48. Middle East & Africa Pneumococcal Vaccine Polyvalent Revenue Market Share by Country (2020-2025)
Table 49. Middle East & Africa Pneumococcal Vaccine Polyvalent Sales by Type (2020-2025) & (K Units)
Table 50. Middle East & Africa Pneumococcal Vaccine Polyvalent Sales by Application (2020-2025) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Pneumococcal Vaccine Polyvalent
Table 52. Key Market Challenges & Risks of Pneumococcal Vaccine Polyvalent
Table 53. Key Industry Trends of Pneumococcal Vaccine Polyvalent
Table 54. Pneumococcal Vaccine Polyvalent Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Pneumococcal Vaccine Polyvalent Distributors List
Table 57. Pneumococcal Vaccine Polyvalent Customer List
Table 58. Global Pneumococcal Vaccine Polyvalent Sales Forecast by Region (2026-2031) & (K Units)
Table 59. Global Pneumococcal Vaccine Polyvalent Revenue Forecast by Region (2026-2031) & ($ millions)
Table 60. Americas Pneumococcal Vaccine Polyvalent Sales Forecast by Country (2026-2031) & (K Units)
Table 61. Americas Pneumococcal Vaccine Polyvalent Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 62. APAC Pneumococcal Vaccine Polyvalent Sales Forecast by Region (2026-2031) & (K Units)
Table 63. APAC Pneumococcal Vaccine Polyvalent Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Europe Pneumococcal Vaccine Polyvalent Sales Forecast by Country (2026-2031) & (K Units)
Table 65. Europe Pneumococcal Vaccine Polyvalent Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. Middle East & Africa Pneumococcal Vaccine Polyvalent Sales Forecast by Country (2026-2031) & (K Units)
Table 67. Middle East & Africa Pneumococcal Vaccine Polyvalent Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Global Pneumococcal Vaccine Polyvalent Sales Forecast by Type (2026-2031) & (K Units)
Table 69. Global Pneumococcal Vaccine Polyvalent Revenue Forecast by Type (2026-2031) & ($ millions)
Table 70. Global Pneumococcal Vaccine Polyvalent Sales Forecast by Application (2026-2031) & (K Units)
Table 71. Global Pneumococcal Vaccine Polyvalent Revenue Forecast by Application (2026-2031) & ($ millions)
Table 72. Merck & Co. Basic Information, Pneumococcal Vaccine Polyvalent Manufacturing Base, Sales Area and Its Competitors
Table 73. Merck & Co. Pneumococcal Vaccine Polyvalent Product Portfolios and Specifications
Table 74. Merck & Co. Pneumococcal Vaccine Polyvalent Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 75. Merck & Co. Main Business
Table 76. Merck & Co. Latest Developments
Table 77. Pfizer Basic Information, Pneumococcal Vaccine Polyvalent Manufacturing Base, Sales Area and Its Competitors
Table 78. Pfizer Pneumococcal Vaccine Polyvalent Product Portfolios and Specifications
Table 79. Pfizer Pneumococcal Vaccine Polyvalent Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 80. Pfizer Main Business
Table 81. Pfizer Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Pneumococcal Vaccine Polyvalent
Figure 2. Pneumococcal Vaccine Polyvalent Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Pneumococcal Vaccine Polyvalent Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Pneumococcal Vaccine Polyvalent Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Pneumococcal Vaccine Polyvalent Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Pneumococcal Vaccine Polyvalent Sales Market Share by Country/Region (2024)
Figure 10. Pneumococcal Vaccine Polyvalent Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Prevnar 13
Figure 12. Product Picture of Pneumovax23
Figure 13. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Type in 2025
Figure 14. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2020-2025)
Figure 15. Pneumococcal Vaccine Polyvalent Consumed in 18 Years and Younger
Figure 16. Global Pneumococcal Vaccine Polyvalent Market: 18 Years and Younger (2020-2025) & (K Units)
Figure 17. Pneumococcal Vaccine Polyvalent Consumed in 19 To 64 Years Old
Figure 18. Global Pneumococcal Vaccine Polyvalent Market: 19 To 64 Years Old (2020-2025) & (K Units)
Figure 19. Pneumococcal Vaccine Polyvalent Consumed in 65 Years and Older
Figure 20. Global Pneumococcal Vaccine Polyvalent Market: 65 Years and Older (2020-2025) & (K Units)
Figure 21. Global Pneumococcal Vaccine Polyvalent Sale Market Share by Application (2024)
Figure 22. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Application in 2025
Figure 23. Pneumococcal Vaccine Polyvalent Sales by Company in 2025 (K Units)
Figure 24. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Company in 2025
Figure 25. Pneumococcal Vaccine Polyvalent Revenue by Company in 2025 ($ millions)
Figure 26. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Company in 2025
Figure 27. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Geographic Region (2020-2025)
Figure 28. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Geographic Region in 2025
Figure 29. Americas Pneumococcal Vaccine Polyvalent Sales 2020-2025 (K Units)
Figure 30. Americas Pneumococcal Vaccine Polyvalent Revenue 2020-2025 ($ millions)
Figure 31. APAC Pneumococcal Vaccine Polyvalent Sales 2020-2025 (K Units)
Figure 32. APAC Pneumococcal Vaccine Polyvalent Revenue 2020-2025 ($ millions)
Figure 33. Europe Pneumococcal Vaccine Polyvalent Sales 2020-2025 (K Units)
Figure 34. Europe Pneumococcal Vaccine Polyvalent Revenue 2020-2025 ($ millions)
Figure 35. Middle East & Africa Pneumococcal Vaccine Polyvalent Sales 2020-2025 (K Units)
Figure 36. Middle East & Africa Pneumococcal Vaccine Polyvalent Revenue 2020-2025 ($ millions)
Figure 37. Americas Pneumococcal Vaccine Polyvalent Sales Market Share by Country in 2025
Figure 38. Americas Pneumococcal Vaccine Polyvalent Revenue Market Share by Country (2020-2025)
Figure 39. Americas Pneumococcal Vaccine Polyvalent Sales Market Share by Type (2020-2025)
Figure 40. Americas Pneumococcal Vaccine Polyvalent Sales Market Share by Application (2020-2025)
Figure 41. United States Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 42. Canada Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 43. Mexico Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 44. Brazil Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 45. APAC Pneumococcal Vaccine Polyvalent Sales Market Share by Region in 2025
Figure 46. APAC Pneumococcal Vaccine Polyvalent Revenue Market Share by Region (2020-2025)
Figure 47. APAC Pneumococcal Vaccine Polyvalent Sales Market Share by Type (2020-2025)
Figure 48. APAC Pneumococcal Vaccine Polyvalent Sales Market Share by Application (2020-2025)
Figure 49. China Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 50. Japan Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 51. South Korea Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 52. Southeast Asia Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 53. India Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 54. Australia Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 55. China Taiwan Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 56. Europe Pneumococcal Vaccine Polyvalent Sales Market Share by Country in 2025
Figure 57. Europe Pneumococcal Vaccine Polyvalent Revenue Market Share by Country (2020-2025)
Figure 58. Europe Pneumococcal Vaccine Polyvalent Sales Market Share by Type (2020-2025)
Figure 59. Europe Pneumococcal Vaccine Polyvalent Sales Market Share by Application (2020-2025)
Figure 60. Germany Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 61. France Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 62. UK Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 63. Italy Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 64. Russia Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 65. Middle East & Africa Pneumococcal Vaccine Polyvalent Sales Market Share by Country (2020-2025)
Figure 66. Middle East & Africa Pneumococcal Vaccine Polyvalent Sales Market Share by Type (2020-2025)
Figure 67. Middle East & Africa Pneumococcal Vaccine Polyvalent Sales Market Share by Application (2020-2025)
Figure 68. Egypt Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 69. South Africa Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 70. Israel Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 71. Turkey Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 72. GCC Countries Pneumococcal Vaccine Polyvalent Revenue Growth 2020-2025 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Pneumococcal Vaccine Polyvalent in 2025
Figure 74. Manufacturing Process Analysis of Pneumococcal Vaccine Polyvalent
Figure 75. Industry Chain Structure of Pneumococcal Vaccine Polyvalent
Figure 76. Channels of Distribution
Figure 77. Global Pneumococcal Vaccine Polyvalent Sales Market Forecast by Region (2026-2031)
Figure 78. Global Pneumococcal Vaccine Polyvalent Revenue Market Share Forecast by Region (2026-2031)
Figure 79. Global Pneumococcal Vaccine Polyvalent Sales Market Share Forecast by Type (2026-2031)
Figure 80. Global Pneumococcal Vaccine Polyvalent Revenue Market Share Forecast by Type (2026-2031)
Figure 81. Global Pneumococcal Vaccine Polyvalent Sales Market Share Forecast by Application (2026-2031)
Figure 82. Global Pneumococcal Vaccine Polyvalent Revenue Market Share Forecast by Application (2026-2031)